Liquid biopsies have clinical utility at many critical decision-making points within a patient’s treatment journey
Liquid Biopsies to Clinical Outcomes
Our Liquid Biopsy technology can offer a broad range of clinical applications throughout a patient’s treatment cycle.
This liquid biopsy approach has potential clinical utility at many critical decision-making points within a patient’s treatment journey, providing Oncologists with a platform for regular, non-invasive, and highly-sensitive tumor profiling.
Liquid biopsies can offer a complete picture of tumor heterogeneity and are available when a tissue biopsy is limited or unobtainable.
Analysis at Every Stage
Liquid biopsy can provide clinically actionable information to physicians at critical stages on a patient’s treatment cycle, from early detection through to personalized and dynamic adaptation of treatment plans.
Liquid biopsies have been shown to accurately identify mutations from circulating tumour DNA (ctDNA) in the blood (Pritchett et al. 2019; Plagnol et al. 2018). This can help the Oncologist to select an appropriate therapy according to clinical guidelines, when tissue is not available.
Monitoring Treatment Response
When a patient starts a new treatment, liquid biopsy provides a novel way of reviewing the treatment’s effectiveness. In the example shown here, liquid biopsy was used to monitor the presence of mutations prior to and during treatment.
Once collected, the blood sample is centrifuged to separate the plasma containing the cell-free DNA from other components. The DNA is then extracted, amplified, and then analyzed for mutations. Being able to analyze the liquid biopsy for multiple mutations simultaneously allows the clinician to better understand the tumor profile and adapt treatment appropriately.
Detecting Disease Relapse
By monitoring ctDNA levels in the blood, it may be possible to track the dynamics of more advanced cancer and identify disease relapse ahead of other methods of detection, such as biomarkers and imaging, as well as measuring risk.
Personalized Treatment Plan
When a patient relapses, as a result of residual disease or resistance to treatment, a liquid biopsy offers their physician an opportunity to identify changes in the tumor profile and react quickly and appropriately.